Tiziana Life Sciences (TLSA) has released an update.
Tiziana Life Sciences has received FDA Fast Track designation for its intranasal foralumab, aiming to treat Secondary Progressive Multiple Sclerosis (SPMS) and potentially other neurodegenerative diseases. The designation will expedite the review process and enhance the company’s interaction with the FDA, highlighting foralumab’s potential to meet an unmet medical need. Additionally, Tiziana is addressing Nasdaq compliance issues to prevent the delisting of its shares.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
